Add-on topiramate for bipolar depression Authors: McIntyre RC, et al. Title: Topiramate versus bupropion SR when added to a mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Reference: Bipolar Disorders 2002;4:207-13. Purpose: To determine the efficacy and tolerability of topiramate and bupropion when added to a mood stabilizer (atypical antipsychotics, lithium, or divalproex) for the treatment of patients with bipolar depression. Study design: Randomized, single-blinded (rater-blinded) study. Follow up: 8 weeks. Patients: 36 outpatients (18 topiramate, 18 bupropion). Treatment: Topiramate 50–300 mg/day or bupropion SR 100–400 mg/day. Results: A significant and similar reduction in the depressive symptoms of patients was observed with both treatments. In addition, both treatments were well tolerated.
